Jasper Therapeutics nears first renal-study readout after July acquisition and $132m raise
The US biotech ended September with $135.3m in cash and expects its first interim kidney data for vensobafusp alfa before the end of the year.
Jasper Therapeutics ended the third quarter with $135.3m in cash. The company has completed two July transactions that reshaped its balance sheet: an all-stock acquisition of Kira Pharmaceuticals and a private placement of preferred stock worth about $132.0m. It disclosed the figures alongside its quarterly results on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.